Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Entrada Therapeutics, Inc. TRDA
$12.12
-$0.03 (-0.25%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
401896992.00000000
-
week52high
24.38
-
week52low
5.43
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-3.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
06 мар 2023 г. в 12:00
Описание компании
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | 16 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| Evercore ISI Group | Outperform | 24 ноя 2021 г. | |
| Goldman Sachs | Neutral | 23 ноя 2021 г. | |
| Cowen & Co. | Outperform | 23 ноя 2021 г. | |
| Goldman Sachs | Neutral | Neutral | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Doshi Dipal | D | 163835 | 2000 | 27 янв 2023 г. |
| Doshi Dipal | D | 165835 | 2410 | 09 янв 2023 г. |
| KREHER NERISSA | D | 15516 | 5200 | 30 дек 2022 г. |
| Doshi Dipal | D | 168245 | 400 | 29 дек 2022 г. |
| Doshi Dipal | D | 168645 | 4521 | 28 дек 2022 г. |
| Doshi Dipal | D | 173166 | 9069 | 27 дек 2022 г. |
| Doshi Dipal | D | 182235 | 600 | 27 дек 2022 г. |
| WENTWORTH KORY JAMES | D | 100947 | 4550 | 08 дек 2022 г. |
| WENTWORTH KORY JAMES | D | 16509 | 4550 | 08 дек 2022 г. |
| WENTWORTH KORY JAMES | A | 21059 | 4550 | 08 дек 2022 г. |
Новостная лента
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
Zacks Investment Research
09 дек 2022 г. в 15:03
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
Entrada Therapeutics shares jump on collaboration with Vertex
Market Watch
08 дек 2022 г. в 08:24
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop treatments for myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness. The collaboration includes Entrada's ENTR-701, which is currently in preclinical studies.
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
30 авг 2022 г. в 07:00
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Nathan Dowden, Chief Operating Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 – 14, 2022.
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
GlobeNewsWire
06 июл 2022 г. в 07:00
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will participate in-person at the William Blair Biotech Focus Conference, to be held in New York from July 12 – 13, 2022.
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
InvestorPlace
07 июн 2022 г. в 13:00
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.